Yahoo
OTC Markets OTCQB - Delayed Quote USD

BetterLife Pharma Inc. (BETRF)

0.1660 -0.0040 (-2.35%)
At close: October 26 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for BETRF
  • Previous Close 0.1700
  • Open 0.1685
  • Bid 0.1583 x 1500000
  • Ask 0.1700 x 6000000
  • Day's Range 0.1685 - 0.1685
  • 52 Week Range 0.0280 - 0.3310
  • Volume 25,000
  • Avg. Volume 138,484
  • Market Cap (intraday) 102.589M
  • Beta (5Y Monthly) 0.22
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

www.abetterlifepharma.com

--

Full Time Employees

January 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/26/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

BETRF
336.84%
S&P/TSX Composite index (^GSPTSE)
12.80%

1-Year Return

BETRF
238.78%
S&P/TSX Composite index (^GSPTSE)
18.42%

3-Year Return

BETRF
260.87%
S&P/TSX Composite index (^GSPTSE)
90.43%

5-Year Return

BETRF
26.87%
S&P/TSX Composite index (^GSPTSE)
69.76%

Statistics

View More

Valuation Measures

Annual
As of 10/23/2026
  • Market Cap

    99.30M

  • Enterprise Value

    103.04M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -140.79%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -3.48M

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    973.59k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -473.77k

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: